According to sources a preventive treatment for dementia may proceed to clinical trials after successful animal testing, say researchers. The research is looking to develop effective immunotherapy via a new vaccine to remove 'brain plaque' and tau protein aggregates linked to Alzheimer's disease. Recent success in bigenic mice models supports progression to human trials in years to come, the research added.
professor Petrovsky said the Advax adjuvant method is a pivotal system to help take the combination MultiTEP-based Aï¿½/tau vaccines therapy, as well as separate vaccines targeting these pathological molecules, to clinical trials perhaps within two years.
"Our approach is looking to cover all bases and get past previous roadblocks in finding a therapy to slow the accumulation of Aï¿½/tau molecules and delay Alzheimer's disease progression in a the rising number of people around the world," Petrovsky added. Several promising drug candidates have failed in clinical trials so the search for new preventions or therapies continues.